|
1
|
Hundal R and Shaffer EA: Gallbladder
cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109.
2014.PubMed/NCBI
|
|
2
|
Lazcano-Ponce EC, Miquel JF, Muñoz N,
Herrero R, Ferrecio C, Wistuba II, de Alonso Ruiz P, Aristi Urista
G and Nervi F: Epidemiology and molecular pathology of gallbladder
cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ding Q, Li M, Wu X, Zhang L, Wu W, Ding Q,
Weng H, Wang X and Liu Y: CLIC1 overexpression is associated with
poor prognosis in gallbladder cancer. Tumour Biol. 36:193–198.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen L, Wang J, Fu L, Zhang B, Zhang H and
Ye B: Prognostic significance of metastasis associated in colon
cancer 1 (MACC1) expression in patients with gallbladder cancer. J
Cancer Res Ther. 10:1052–1056. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nigam J, Chandra A, Kazmi HR, Parmar D,
Singh D and Gupta V: Prognostic significance of survivin in
resected gallbladder cancer. J Surg Res. 194:57–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groot Koerkamp B and Fong Y: Outcomes in
biliary malignancy. J Surg Oncol. 110:585–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Narang AK, Sugar EA, Luber B,
Rosati LM, Hsu CC, Fuller CD, Pawlik TM, Miller RC, Czito BG, et
al: Evaluation of adjuvant radiation therapy for resected
gallbladder carcinoma: A multi-institutional experience. Ann Surg
Oncol. 2015.
|
|
9
|
Weatherall TJ, Fenton M, Munene G, Dickson
PV and Deneve JL: Locally advanced, unresectable squamous cell
carcinoma of the gallbladder. Case Rep Surg.
2015:4246502015.PubMed/NCBI
|
|
10
|
Yang XW, Yuan JM, Chen JY, Yang J, Gao QG,
Yan XZ, Zhang BH, Feng S and Wu MC: The prognostic importance of
jaundice in surgical resection with curative intent for gallbladder
cancer. BMC Cancer. 14:6522014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niu GC, Shen CM, Cui W and Li Q: Surgical
treatment of advanced gallbladder cancer. Am J Clin Oncol. 38:5–10.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Higuchi R, Ota T, Araida T, Kajiyama H,
Yazawa T, Furukawa T, Yoshikawa T, Takasaki K and Yamamoto M:
Surgical approaches to advanced gallbladder cancer: A 40-year
single-institution study of prognostic factors and resectability.
Ann Surg Oncol. 21:4308–4316. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JO, Oh DY, Hsu C, Chen JS, Chen LT,
Orlando M, Kim JS and Lim HY: Gemcitabine plus cisplatin for
advanced biliary tract cancer: A systematic review. Cancer Res
Treat. 47:343–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alberts SR, Al-Khatib H, Mahoney MR,
Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE,
Knost JA and Tschetter LK: Gemcitabine, 5-fluorouracil and
leucovorin in advanced biliary tract and gallbladder carcinoma: A
North Central Cancer Treatment Group phase II trial. Cancer.
103:111–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno H, Okusaka T, Ikeda M, Takezako Y and
Morizane C: Phase II study of S-1 in patients with advanced biliary
tract cancer. Br J Cancer. 91:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito H, Takada T, Miyazaki M, Miyakawa S,
Tsukada K, Nagino M, Kondo S, Furuse J, Tsuyuguchi T, Kimura F, et
al: Radiation therapy and photodynamic therapy for biliary tract
and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 15:63–68.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Du Y, Liu X, Cho WC and Yang Y:
MicroRNAs as regulator of signaling networks in metastatic colon
cancer. Biomed Res Int. 2015:8236202015.PubMed/NCBI
|
|
19
|
Orellana EA and Kasinski AL: MicroRNAs in
cancer: A historical perspective on the path from discovery to
therapy. Cancers (Basel). 7:1388–1405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kishikawa T, Otsuka M, Ohno M, Yoshikawa
T, Takata A and Koike K: Circulating RNAs as new biomarkers for
detecting pancreatic cancer. World J Gastroenterol. 21:8527–8540.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelly BD, Miller N, Sweeney KJ, Durkan GC,
Rogers E, Walsh K and Kerin MJ: A circulating microRNA signature as
a biomarker for prostate cancer in a high-risk group. J Clin Med.
4:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and
Xiang Y: Expression profile of circulating microRNAs as a promising
fingerprint for cervical cancer diagnosis and monitoring. Mol Clin
Oncol. 3:851–858. 2015.PubMed/NCBI
|
|
24
|
Karimi Kurdistani Z, Saberi S, Tsai KW and
Mohammadi M: MicroRNA-21: Mechanisms of oncogenesis and its
application in diagnosis and prognosis of gastric cancer. Arch Iran
Med. 18:524–536. 2015.PubMed/NCBI
|
|
25
|
Fang Z, Tang J, Bai Y, Lin H, You H, Jin
H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24,
microRNA-320a and microRNA-423-5p are potential biomarkers for
colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li G and Pu Y: MicroRNA signatures in
total peripheral blood of gallbladder cancer patients. Tumour Biol.
36:6985–6990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peterson SM, Thompson JA, Ufkin ML,
Sathyanarayana P, Liaw L and Congdon CB: Common features of
microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galli V, Guzman F, de Oliveira LF,
Loss-Morais G, Körbes AP, Silva SD, Margis-Pinheiro MM and Margis
R: Identifying microRNAs and transcript targets in Jatropha seeds.
PLoS One. 9:e837272014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shi Q and Yang X: Circulating microRNA and
long noncoding RNA as biomarkers of cardiovascular diseases. J Cell
Physiol. 2015.
|
|
34
|
Ha TY: MicroRNAs in human diseases: From
lung, liver and kidney diseases to infectious disease, sickle cell
disease and endometrium disease. Immune Netw. 11:309–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Srivastava SP, Koya D and Kanasaki K:
MicroRNAs in kidney fibrosis and diabetic nephropathy: Roles on EMT
and EndMT. Biomed Res Int. 2013:1254692013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bekris LM and Leverenz JB: The biomarker
and therapeutic potential of miRNA in Alzheimer's disease.
Neurodegener Dis Manag. 5:61–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar Shamsuzzama L, Haque R and Nazir A:
Role of microRNA Let-7 in modulating multifactorial aspect of
neurodegenerative diseases: An overview. Mol Neurobiol. 2015.(Epub
ahead of print).
|
|
38
|
Xue J, Chen Z, Gu X, Zhang Y and Zhang W:
MicroRNA-148a inhibits migration of breast cancer cells by
targeting MMP-13. Tumour Biol. 2015.(Epub ahead of print).
|
|
39
|
Tong Z, Liu N, Lin L, Guo X, Yang D and
Zhang Q: miR-125a-5p inhibits cell proliferation and induces
apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1.
Biomed Pharmacother. 75:129–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li W, Zhang J, Chen T, Yin P, Yang J and
Cao Y: MiR-132 upregulation promotes gastric cancer cell growth
through suppression of FoxO1 translation. Tumour Biol. 2015.
|
|
41
|
Farra R, Grassi M, Grassi G and Dapas B:
Therapeutic potential of small interfering RNAs/micro interfering
RNA in hepatocellular carcinoma. World J Gastroenterol.
21:8994–9001. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Srivastava K, Srivastava A and Mittal B:
Common genetic variants in pre-microRNAs and risk of gallbladder
cancer in North Indian population. J Hum Genet. 55:495–499. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kono H, Nakamura M, Ohtsuka T, Nagayoshi
Y, Mori Y, Takahata S, Aishima S and Tanaka M: High expression of
microRNA-155 is associated with the aggressive malignant behavior
of gallbladder carcinoma. Oncol Rep. 30:17–24. 2013.PubMed/NCBI
|
|
44
|
Peng HH, Zhang YD, Gong LS, Liu WD and
Zhang Y: Increased expression of microRNA-335 predicts a favorable
prognosis in primary gallbladder carcinoma. Onco Targets Ther.
6:1625–1630. 2013.PubMed/NCBI
|
|
45
|
Li Z, Yu X, Shen J, Law PT, Chan MT and Wu
WK: MicroRNA expression and its implications for diagnosis and
therapy of gallbladder cancer. Oncotarget. 6:13914–13921. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding
J, Liang L, Hu J, Shen H, Chen Z, et al: MicroRNA-26a acts as a
tumor suppressor inhibiting gallbladder cancer cell proliferation
by directly targeting HMGA2. Int J Oncol. 44:2050–2058.
2014.PubMed/NCBI
|
|
47
|
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding
J, Liang L, Yang G, Chen Z, Ma B and Yin B: MicroRNA-135a acts as a
putative tumor suppressor by directly targeting very low density
lipoprotein receptor in human gallbladder cancer. Cancer Sci.
105:956–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Letelier P, García P, Leal P, Álvarez H,
Ili C, López J, Castillo J, Brebi P and Roa JC: miR-1 and miR-145
act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin
Exp Pathol. 7:1849–1867, eCollection 2014. 2014.PubMed/NCBI
|
|
49
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin PL, Wu DW, Huang CC, He TY, Chou MC,
Sheu GT and Lee H: MicroRNA-21 promotes tumour malignancy via
increased nuclear translocation of β-catenin and predicts poor
outcome in APC-mutated but not in APC-wild-type colorectal cancer.
Carcinogenesis. 35:2175–2182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guo Q, Zhang H, Zhang L, He Y, Weng S,
Dong Z, Wang J, Zhang P and Nao R: MicroRNA-21 regulates non-small
cell lung cancer cell proliferation by affecting cell apoptosis via
COX-19. Int J Clin Exp Med. 8:8835–8841, eCollection 2015.
2015.PubMed/NCBI
|
|
52
|
Lu L, Byrnes K, Han C, Wang Y and Wu T:
miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol
Cancer Res. 12:890–900. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kitamura T, Connolly K, Ruffino L, Ajiki
T, Lueckgen A, DiGiovanni J and Kiguchi K: The therapeutic effect
of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma
in BK5.erbB2 mice. J Hepatol. 57:84–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sekine S, Shimada Y, Nagata T, Sawada S,
Yoshioka I, Matsui K, Moriyama M, Omura T, Osawa S, Shibuya K, et
al: Role of aquaporin-5 in gallbladder carcinoma. Eur Surg Res.
51:108–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao S, Yao D, Chen J and Ding N:
Circulating miRNA-20a and miRNA-203 for screening lymph node
metastasis in early stage cervical cancer. Genet Test Mol
Biomarkers. 17:631–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mitani Y, Roberts DB, Fatani H, Weber RS,
Kies MS, Lippman SM and El-Naggar AK: MicroRNA profiling of
salivary adenoid cystic carcinoma: Association of miR-17-92
upregulation with poor outcome. PLoS One. 8:e667782013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y
and Fan D: miR-19b/20a/92a regulates the self-renewal and
proliferation of gastric cancer stem cells. J Cell Sci.
126:4220–4229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xiong Y, Zhang L and Kebebew E: miR-20a is
upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS
One. 9:e961032014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qiang XF, Zhang ZW, Liu Q, Sun N, Pan LL,
Shen J, Li T, Yun C, Li H and Shi LH: miR-20a promotes prostate
cancer invasion and migration through targeting ABL2. J Cell
Biochem. 115:1269–1276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chang Y, Liu C, Yang J, Liu G, Feng F,
Tang J, Hu L, Li L, Jiang F, Chen C, et al: miR-20a triggers
metastasis of gallbladder carcinoma. J Hepatol. 59:518–527. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Osaka E, Kelly AD, Spentzos D, Choy E,
Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ and Duan Z:
MicroRNA-155 expression is independently predictive of outcome in
chordoma. Oncotarget. 6:9125–9139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Peng Y, Dong W, Lin TX, Zhong GZ, Liao B,
Wang B, Gu P, Huang L, Xie Y, Lu FD, et al: MicroRNA-155 promotes
bladder cancer growth by repressing the tumor suppressor DMTF1.
Oncotarget. 6:16043–16058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang P, Zhu CF, Ma MZ, Chen G, Song M,
Zeng ZL, Lu WH, Yang J, Wen S, Chiao PJ, et al: Micro-RNA-155 is
induced by K-Ras oncogenic signal and promotes ROS stress in
pancreatic cancer. Oncotarget. 6:21148–21158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gasparini P, Cascione L, Fassan M, Lovat
F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and
Huebner K: MicroRNA expression profiling identifies a four microRNA
signature as a novel diagnostic and prognostic biomarker in triple
negative breast cancers. Oncotarget. 5:1174–1184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang PY, Gong HT, Li BF, Lv CL, Wang HT,
Zhou HH, Li XX, Xie SY and Jiang BF: Higher expression of
circulating miR-182 as a novel biomarker for breast cancer. Oncol
Lett. 6:1681–1686. 2013.PubMed/NCBI
|
|
66
|
Du C, Weng X, Hu W, Lv Z, Xiao H, Ding C,
Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: Hypoxia-inducible
miR-182 promotes angiogenesis by targeting RASA1 in hepatocellular
carcinoma. J Exp Clin Cancer Res. 34:672015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang L, Mao P, Song L, Wu J, Huang J, Lin
C, Yuan J, Qu L, Cheng SY and Li J: miR-182 as a prognostic marker
for glioma progression and patient survival. Am J Pathol.
177:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu R, Li J, Teng Z, Zhang Z and Xu Y:
Overexpressed microRNA-182 promotes proliferation and invasion in
prostate cancer PC-3 cells by down-regulating N-myc downstream
regulated gene 1 (NDRG1). PLoS One. 8:e689822013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Qiu Y, Luo X, Kan T, Zhang Y, Yu W, Wei Y,
Shen N, Yi B and Jiang X: TGF-β upregulates miR-182 expression to
promote gallbladder cancer metastasis by targeting CADM1. Mol
Biosyst. 10:679–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yu J, Wang Y, Dong R, Huang X, Ding S and
Qiu H: Circulating microRNA-218 was reduced in cervical cancer and
correlated with tumor invasion. J Cancer Res Clin Oncol.
138:671–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cheng Y, Yang X, Deng X, Zhang X, Li P,
Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell
proliferation, migration and invasion by targeting BMI-1. Tumour
Biol. 36:8015–8023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Han G, Fan M and Zhang X: MicroRNA-218
inhibits prostate cancer cell growth and promotes apoptosis by
repressing TPD52 expression. Biochem Biophys Res Commun.
456:804–809. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu Z, Xu Y, Long J, Guo K, Ge C and Du R:
MicroRNA-218 suppresses the proliferation, invasion and promotes
apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J
Cancer Res. 27:247–257. 2015.PubMed/NCBI
|
|
74
|
Tian H, Hou L, Xiong YM, Huang JX, She YJ,
Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the
chemosensitivity of esophageal squamous cell carcinoma to
cisplatin. Oncol Rep. 33:981–989. 2015.PubMed/NCBI
|
|
75
|
Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY,
Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder
cancer development via negative modulation of miRNA-218-5p. Cell
Death Dis. 6:e15832015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W
and Sun W: Genetic variation in a miR-335 binding site in BIRC5
alters susceptibility to lung cancer in Chinese Han populations.
Biochem Biophys Res Commun. 430:529–534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dohi O, Yasui K, Gen Y, Takada H, Endo M,
Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N, et al:
Epigenetic silencing of miR-335 and its host gene MEST in
hepatocellular carcinoma. Int J Oncol. 42:411–418. 2013.PubMed/NCBI
|
|
78
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sun Z, Zhang Z, Liu Z, Qiu B, Liu K and
Dong G: MicroRNA-335 inhibits invasion and metastasis of colorectal
cancer by targeting ZEB2. Med Oncol. 31:9822014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gao L, Yang Y, Xu H, Liu R, Li D, Hong H,
Qin M and Wang Y: miR-335 functions as a tumor suppressor in
pancreatic cancer by targeting OCT4. Tumour Biol. 35:8309–8318.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao
H, Li C, Chen Y and Zhao J: miR-34 is associated with poor
prognosis of patients with gallbladder cancer through regulating
telomere length in tumor stem cells. Tumour Biol. 35:1503–1510.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Basu N, Skinner HG, Litzelman K,
Vanderboom R, Baichoo E and Boardman LA: Telomeres and telomere
dynamics: Relevance to cancers of the GI tract. Expert Rev
Gastroenterol Hepatol. 7:733–748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long
G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion
and migration in human breast cancer by targeting the RAB5A. Int J
Clin Exp Pathol. 8:384–393, eCollection 2015. 2015.PubMed/NCBI
|
|
85
|
Li B, Huang P, Qiu J, Liao Y, Hong J and
Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma
and associates with poor prognosis. Med Oncol. 31:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Ma MZ, Li CX, Zhang Y, Weng MZ, Zhang MD,
Qin YY, Gong W and Quan ZW: Long non-coding RNA HOTAIR, a c-Myc
activated driver of malignancy, negatively regulates miRNA-130a in
gallbladder cancer. Mol Cancer. 13:1562014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B,
Zhou L, Song WJ and Dou KF: MicroRNA-135a inhibits cell
proliferation by targeting Bmi1 in pancreatic ductal
adenocarcinoma. Int J Biol Sci. 10:733–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC,
Lee JH, Lee SS, Ashktorab H, Smoot DT, Ryu KW, et al: MicroRNA 135a
suppresses lymph node metastasis through down-regulation of ROCK1
in early gastric cancer. PLoS One. 9:e852052014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tang W, Jiang Y, Mu X, Xu L, Cheng W and
Wang X: miR-135a functions as a tumor suppressor in epithelial
ovarian cancer and regulates HOXA10 expression. Cell Signal.
26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Yang X, Zhang XF, Lu X, Jia HL, Liang L,
Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in
human hepatocellular carcinoma by targeting hepatocyte growth
factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu P, Tang H, Chen B, He Z, Deng M, Wu M,
Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour
proliferation and metastasis by targeting metadherin in triple
negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shen C, Yang H, Liu H, Wang X, Zhang Y and
Xu R: Inhibitory effect and mechanisms of microRNA-146b-5p on the
proliferation and metastatic potential of Caski human cervical
cancer cells. Mol Med Rep. 11:3955–3961. 2015.PubMed/NCBI
|
|
93
|
Lin F, Wang X, Jie Z, Hong X, Li X, Wang M
and Yu Y: Inhibitory effects of miR-146b-5p on cell migration and
invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ
Sci Technolog Med Sci. 31:509–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wu PY, Zhang XD, Zhu J, Guo XY and Wang
JF: Low expression of microRNA-146b-5p and microRNA-320d predicts
poor outcome of large B-cell lymphoma treated with
cyclophosphamide, doxorubicin, vincristine and prednisone. Hum
Pathol. 45:1664–1673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Katakowski M, Zheng X, Jiang F, Rogers T,
Szalad A and Chopp M: miR-146b-5p suppresses EGFR expression and
reduces in vitro migration and invasion of glioma. Cancer Invest.
28:1024–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cai J, Xu L, Cai Z, Wang J, Zhou B and Hu
H: MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by
targeting epidermal growth factor receptor. Mol Med Rep.
12:1549–1555. 2015.PubMed/NCBI
|
|
97
|
Gupta A, Sharma A, Yadav A, Rastogi N,
Agrawal S, Kumar A, Kumar V, Misra S and Mittal B: Evaluation of
miR-27a, miR-181a and miR-570 genetic variants with gallbladder
cancer susceptibility and treatment outcome in a north indian
population. Mol Diagn Ther. 19:317–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
